Recent Press Releases 04.02.2020 Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab) 04.02.2020 Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors 04.01.2020 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 03.27.2020 Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact 03.26.2020 Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn 03.24.2020 U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis 03.18.2020 Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns 03.18.2020 Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older 03.18.2020 Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch 03.17.2020 Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts 1 of 160 next › Media Contacts Get to Know Us Company Fact Sheet Featured Stories Press Kits @Pfizer @Pfizer_News by pfizer Tweets by pfizer_news
